2018 is just about over, in the minds of some investors

"We expect investors will soon look past 2018 and focus on 2019 growth," says Goldman Sachs strategist David Kostin. "For many years, beginning in July investors would start to value stocks based on the following year's profit outlook." That's almost hard to believe this go around as markets continue to be very daily headline driven. To that end, focusing on 2019 in July 2018 may prove to be a money-losing proposition for investors. 

Nevertheless, much of the Wall Street's smart money will extract themselves from trading the news cycle and place bets on 2019 from exotic beaches this summer. Goldman Sachs believes the best stocks to play in a year of rising interest rates and less of a tax reform bump are those companies with strong sales growth potential. Wall Street is modeling for 2019 S&P 500 sales growth of 5% -- Goldman's new "high revenue growth stock basket" could notch sales growth of 12% in 2019.

The hot list:

  1. Align Technology (ALGN) (+22% revenue growth estimate)
  2. Amazon (AMZN) (+22%)
  3. Autodesk (ADSK) (+27%)
  4. Cabot Oil & Gas (COG) (+34%)
  5. Concho Resources (CXO) (+30%)
  6. Facebook (FB) (+27%)
  7. Netflix (NFLX) (+25%)
  8. Pentair (PNR) (+22%)
  9. Vertex Pharmaceuticals (VRTX) (+22)

"Firms with high revenue growth should outperform the S&P 500 during the next 12 months as the index climbs by 6% to our target of 2875," says Kostin. 

Now get to researching those nine names. 

Amazon and Facebook are holdings in Jim Cramer's Action Alerts PLUS.

More from Investing

Papa John's: The Noise and the Stock Price

Papa John's: The Noise and the Stock Price

CSX Rises on Earnings, Revenue Beat

CSX Rises on Earnings, Revenue Beat

United Beats Second Quarter Earnings Estimates

United Beats Second Quarter Earnings Estimates

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer